GT

Getinge ABDUS Getinge Stock Report

Last reporting period 30 Sep, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

3.236

Middle

Exchange

XDUS - Boerse Duesseldorf

GTN.DU Stock Analysis

GT

Avoid

Based on Eyestock quantitative analysis, GTN.DU`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

45/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-19.5 %

Overvalued

Market cap $B

3.236

Dividend yield

3.74 %

Shares outstanding

254.15 B

Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. The company is headquartered in Goeteborg, Vastra Gotalands. The firm provides hospitals and Life Science institutions with products and solutions aimed at improving clinical outcomes and optimizing workflows. The Company’s reporting segments have the following activities: Acute Care Therapies develops solutions for life-sustaining care in acute health conditions. Life Science offers a comprehensive range of equipment, technical expertise and prevention consultation contamination in pharmaceutical production, biomedical research, production of medical equipment and in various laboratory applications. Surgical Workflows offers products and services for the effective disinfection and sterilization of instruments used in operations, operating tables and others hardware for operating rooms and advanced IT systems for efficient and secure workflows in hospitals.

View Section: Eyestock Rating